国产去甲氧柔红霉素联合阿糖胞苷和依托泊苷治疗难治性急性髓系白血病17例

Idarubicin in combination with Ara-C and VP16 for treatment of refractory acute myelocytic leukemia

目的观察国产去甲氧柔红霉素（IDA）联合阿糖胞苷（Ara-C）和依托泊苷（VP16）组成的IAE方案治疗难治性急性髓系白血病（AML）的疗效。方法IDA7mg／m^2静脉滴注连续3d，Ara—C100mg／m^2和VP16 100mg／d均静脉滴注连续5d为1个疗程。结果17例患者中，完全缓解（CR）9例，52．9％；部分缓解（PR）4例，23．9％；未缓解3例，脑出血死亡1例。结论IAE方案治疗难治性白血病疗效较好，主要不良反应为骨髓抑制、粒细胞减少及血小板减少。未发现心、肝、肾毒副作用。

Objective To investigate the curative effect of the Idarubicin（IDA） in combination with Ara-C and VP16 （IAE） regimen for treatment on refractory acute myelocytic leukemia. Methods Idarubicin 7 mg/m^2 iv gtt for 3 days, Ara-C 100 mg/m^2 and VP16 100 mg/d iv gtt for 5 days continuously were used as one course. Results Among 17 refractory leukemia patients complete remission was achieved in 9 patients and partial remission in 4 patients, but no remission in 3 patients and one patient died of cerebral hemorrhage after one-two courses of the treatment. Conclusion The IAE regimen for treatment of refractory acute myeloeytie leukemia is an effective therapy. The major toxic side effects encountered were marrow suppression, neutropenia and thrombocytopenia. The toxic side effects in heart, liver and kidney were not found.